Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated: April 2, 2026, 2:35 am
Author: Getaka|Social: XLinkedIn
Stock Ticker - BSE: 533573 | NSE: APLLTD

Alembic Pharmaceuticals Ltd: Intrinsic Value & Share Price Analysis

Fair Value

₹504.82Overvalued by 25.43%vs CMP ₹677.00

P/E (20.1) × ROE (11.4%) × BV (₹271.00) × DY (1.62%)

₹436.50Overvalued by 35.52%vs CMP ₹677.00
MoS: -55.1% (Negative)Confidence: 63/100 (Moderate)Models: 1 Fair, 8 Over
ModelCategoryValueWeightSignal
PE-ROEEarnings₹524.2022%Over (-22.6%)
Graham NumberEarnings₹441.6516%Over (-34.8%)
Earnings PowerEarnings₹156.4211%Over (-76.9%)
DCFCash Flow₹335.4513%Over (-50.5%)
Net Asset ValueAssets₹270.597%Over (-60%)
EV/EBITDAEnterprise₹578.979%Over (-14.5%)
Earnings YieldEarnings₹319.907%Over (-52.7%)
ROCE CapitalReturns₹735.679%Fair (+8.7%)
Revenue MultipleRevenue₹509.125%Over (-24.8%)
Consensus (9 models)₹436.50100%Overvalued
Key Drivers: Wide model spread (₹156–₹736) — high uncertainty.

PE-ROE · Graham · EPV · DCF · NAV · EV/EBITDA · DDM · Earnings Yield · ROCE Capital · Revenue Multiple | CoE: 12% · Terminal: 4% · EPS CAGR: 3.8%

*Investments are subject to market risks

Investment Snapshot

64
Alembic Pharmaceuticals Ltd scores 64/100 (Average)
Based on 5 dimensions: health, institutional flow, earnings quality, momentum, and peer comparison
Stock Health76/100 · Strong
ROCE 13.0% GoodROE 11.4% AverageD/E 0.03 Low debtInterest Coverage 0.0x RiskyProfitable 5/5 years Consistent
Smart Money60/100 · Moderate
FII holding up 0.29% (6mo) Slight increasePromoter holding at 69.7% Stable
Earnings Quality50/100 · Moderate
OPM stable around 15% Steady
Quarterly Momentum68/100 · Strong
Revenue (4Q): +13% YoY GrowingProfit (4Q): +4% YoY Positive
Industry Rank60/100 · Moderate
P/E 20.1 vs industry 53.8 Cheaper than peersROCE 13.0% vs industry 16.4% Average3Y sales CAGR: 8% Slow

Weights: Health 30% · Earnings Quality 25% · Momentum 20% · Industry Rank 15% · Smart Money 10%. Scores are computed from reported financials and recalculated daily. Not investment advice.

Share Price and Basic Stock Data

Last Updated: April 2, 2026, 2:35 am

Market Cap 13,308 Cr.
Current Price 677
Intrinsic Value₹436.50
High / Low 1,108/635
Stock P/E20.1
Book Value 271
Dividend Yield1.62 %
ROCE13.0 %
ROE11.4 %
Face Value 2.00
PEG Ratio5.24

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Alembic Pharmaceuticals Ltd

Competitors

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
Alembic Pharmaceuticals Ltd 13,308 Cr. 677 1,108/63520.1 2711.62 %13.0 %11.4 % 2.00
Jubilant Pharmova Ltd 13,008 Cr. 817 1,250/78428.2 4140.61 %9.54 %9.55 % 1.00
Caplin Point Laboratories Ltd 11,935 Cr. 1,570 2,397/1,50019.4 4160.38 %25.8 %22.7 % 2.00
Cohance Lifesciences Ltd 11,934 Cr. 312 1,250/26739.7 99.00.00 %14.9 %12.7 % 1.00
Granules India Ltd 15,242 Cr. 628 640/41228.0 1640.24 %15.1 %13.9 % 1.00
Industry Average19,815.15 Cr1,053.8453.84201.200.39%16.35%15.16%6.10

All Competitor Stocks of Alembic Pharmaceuticals Ltd

Quarterly Result

MetricDec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales 1,5091,4061,4861,5951,6311,5171,5621,6481,6931,7701,7111,9101,876
Expenses 1,2741,2031,2871,3871,3641,2571,3251,4091,4331,4981,4301,5941,585
Operating Profit 235204199208266260237239260271281316292
OPM % 16%14%13%13%16%17%15%15%15%15%16%17%16%
Other Income 01121034230101468-27
Interest 15141416151113192225242423
Depreciation 67746668696969717069747680
Profit before tax 154116130135185183157180178192190224162
Tax % 21%-31%7%-1%2%3%14%15%23%18%19%18%18%
Net Profit 122153121137180178135153138157154184132
EPS in Rs 6.207.766.146.959.189.076.857.807.047.987.859.406.76

Last Updated: February 6, 2026, 7:47 pm

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: February 18, 2026, 6:16 pm

MetricMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales 1,8632,0563,1663,1053,1313,9354,6065,3935,3065,6536,2296,6727,267
Expenses 1,5061,6532,1592,4902,4883,0613,3833,9134,4324,9705,2965,6646,107
Operating Profit 3584031,0076156438741,2231,4808746829321,0081,160
OPM % 19%20%32%20%21%22%27%27%16%12%15%15%16%
Other Income 447279-398756-228562
Interest 1045531827161850567996
Depreciation 40447283105115157183287275273279299
Profit before tax 3113599365295417491,0001,368625355632707767
Tax % 24%21%23%23%22%21%20%19%17%4%3%18%
Net Profit 2362837204034135838011,146521342616582626
EPS in Rs 12.4915.0138.2021.3921.8931.0043.9758.3326.5017.4031.3329.6831.99
Dividend Payout % 24%23%9%19%18%18%23%24%38%46%35%37%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2014-20152015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-20232023-20242024-2025
YoY Net Profit Growth (%)19.92%154.42%-44.03%2.48%41.16%37.39%43.07%-54.54%-34.36%80.12%-5.52%
Change in YoY Net Profit Growth (%)0.00%134.50%-198.44%46.51%38.68%-3.77%5.68%-97.61%20.18%114.47%-85.64%

Alembic Pharmaceuticals Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:12%
5 Years:8%
3 Years:8%
TTM:8%
Compounded Profit Growth
10 Years:7%
5 Years:-8%
3 Years:3%
TTM:-6%
Stock Price CAGR
10 Years:4%
5 Years:1%
3 Years:14%
1 Year:-14%
Return on Equity
10 Years:18%
5 Years:13%
3 Years:11%
Last Year:11%

Last Updated: September 4, 2025, 10:45 pm

Balance Sheet

Last Updated: December 10, 2025, 2:20 am

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital 38383838383838393939393939
Reserves 6388471,5601,8652,1822,6813,1825,0285,1984,3314,7795,1525,280
Borrowings 109264114897081,1281,7475847177225131,2581,489
Other Liabilities 4324937186981,0139311,0221,0581,1671,0901,1141,3241,589
Total Liabilities 1,2171,6412,4292,6893,9414,7785,9896,7097,1226,1836,4467,7738,397
Fixed Assets 3975477087999931,1581,5521,7881,7982,3982,5472,5242,834
CWIP 2183933961,0101,5511,8462,1832,304601524837903
Investments 3287504249182361189693127129
Other Assets 7961,0091,5411,4441,8962,0192,5732,5022,9023,0873,2814,2854,531
Total Assets 1,2171,6412,4292,6893,9414,7785,9896,7097,1226,1836,4467,7738,397

Reserves and Borrowings Chart

Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity + 2401729483293128124491,46355272480388
Cash from Investing Activity + -81-256-307-486-884-756-731-840-372-448-321-568
Cash from Financing Activity + -15187-224-12950359155-597-217-262-438444
Net Cash Flow 83417-286-69115-12726-371445-37
Free Cash Flow 158-52647348-49549-285804128282487-466
CFO/OP 86%60%114%73%70%112%56%115%77%115%88%16%

Free Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Free Cash Flow249.00139.00-113.00526.00-65.00873.000.00-583.00157.00-40.00419.000.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days 546440406145692456686077
Inventory Days 159196266269302356417431406315350466
Days Payable 148166264213313237220194178145157179
Cash Conversion Cycle 6594429651164266261283237253363
Working Capital Days 453236616924507374778887
ROCE %44%38%66%29%22%23%24%26%11%7%13%13%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthMar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Promoters 69.61%69.61%69.61%69.61%69.61%69.61%69.61%69.61%69.67%69.68%69.74%69.74%
FIIs 4.55%4.34%4.51%4.52%4.46%4.32%3.94%4.17%3.94%3.96%4.04%4.23%
DIIs 13.32%13.65%14.22%14.51%15.39%15.47%16.05%16.05%16.43%16.46%16.30%16.17%
Public 12.53%12.39%11.67%11.36%10.54%10.61%10.38%10.17%9.96%9.91%9.92%9.84%
No. of Shareholders 99,52297,60789,55285,21276,56774,82991,42993,94491,33689,01389,96987,000

Shareholding Pattern Chart

No. of Shareholders

Alembic Pharmaceuticals Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)Previous Number of SharesPrevious DatePercentage Change
Kotak Small Cap Fund 3,427,766 1.64 268.46N/AN/AN/A
DSP Mid Cap Fund 2,122,883 0.87 166.262,129,8892025-12-15 00:56:17-0.33%
ICICI Prudential Pharma Healthcare & Diagnostics (P.H.D) Fund 1,523,120 1.79 119.291,443,3862026-02-20 08:10:255.52%
DSP Small Cap Fund 1,500,000 0.73 117.481,409,0912025-12-08 05:15:136.45%
Axis Small Cap Fund 1,455,416 0.45 113.99N/AN/AN/A
DSP ELSS Tax Saver Fund 1,434,898 0.65 112.381,252,6672025-12-08 05:15:1314.55%
DSP Healthcare Fund 1,428,180 3.76 111.861,423,5632025-12-08 05:15:130.32%
DSP Aggressive Hybrid Fund 810,789 0.54 63.5N/AN/AN/A
DSP Large Cap Fund 608,603 0.67 47.67N/AN/AN/A
ICICI Prudential Smallcap Fund 511,206 0.49 40.04477,1052026-02-21 21:53:207.15%

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 25Mar 24Mar 23Mar 22Mar 21
FaceValue 2.002.002.002.002.00
Basic EPS (Rs.) 29.6831.3317.4026.5060.81
Diluted EPS (Rs.) 29.6831.3317.4026.5060.81
Cash EPS (Rs.) 43.7445.2532.9940.8366.05
Book Value[Excl.RevalReserv]/Share (Rs.) 264.10245.14222.36266.47257.80
Book Value[Incl.RevalReserv]/Share (Rs.) 264.10245.14222.36266.47257.80
Revenue From Operations / Share (Rs.) 339.46316.90287.59269.95274.39
PBDIT / Share (Rs.) 53.4648.9336.1847.0479.75
PBIT / Share (Rs.) 39.2935.0522.1732.4570.42
PBT / Share (Rs.) 35.9432.2019.6131.5569.60
Net Profit / Share (Rs.) 29.5731.3818.9726.2356.72
NP After MI And SOA / Share (Rs.) 29.6831.3317.4026.5059.94
PBDIT Margin (%) 15.7415.4312.5817.4229.06
PBIT Margin (%) 11.5711.067.7012.0225.66
PBT Margin (%) 10.5810.156.8211.6825.36
Net Profit Margin (%) 8.719.906.599.7120.67
NP After MI And SOA Margin (%) 8.749.886.059.8121.84
Return on Networth / Equity (%) 11.2312.787.829.9422.97
Return on Capital Employeed (%) 14.4013.809.5811.7925.49
Return On Assets (%) 7.509.555.537.3117.56
Long Term Debt / Equity (X) 0.000.000.000.000.03
Total Debt / Equity (X) 0.230.080.140.120.03
Asset Turnover Ratio (%) 0.930.980.770.730.79
Current Ratio (X) 1.692.121.781.672.01
Quick Ratio (X) 0.740.980.870.720.85
Inventory Turnover Ratio (X) 3.390.890.860.780.93
Dividend Payout Ratio (NP) (%) 37.0625.5357.4752.820.00
Dividend Payout Ratio (CP) (%) 25.0817.6931.8334.060.00
Earning Retention Ratio (%) 62.9474.4742.5347.180.00
Cash Earning Retention Ratio (%) 74.9282.3168.1765.940.00
Interest Coverage Ratio (X) 13.3417.1114.1752.1597.85
Interest Coverage Ratio (Post Tax) (X) 8.2111.988.4330.0870.59
Enterprise Value (Cr.) 19368.4619611.9710301.5015131.7919003.45
EV / Net Operating Revenue (X) 2.903.151.822.853.52
EV / EBITDA (X) 18.4320.3914.4916.3712.12
MarketCap / Net Operating Revenue (X) 2.743.101.722.753.52
Retention Ratios (%) 62.9374.4642.5247.170.00
Price / BV (X) 3.524.012.232.783.70
Price / Net Operating Revenue (X) 2.743.101.722.753.52
EarningsYield 0.030.030.030.030.06

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

About the Company - Qualitative Analysis

Alembic Pharmaceuticals Ltd. is a Public Limited Listed company incorporated on 16/06/2010 and has its registered office in the State of Gujarat, India. Company's Corporate Identification Number(CIN) is L24230GJ2010PLC061123 and registration number is 061123. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company's Total Operating Revenue is Rs. 6032.63 Cr. and Equity Capital is Rs. 39.31 Cr. for the Year ended 31/03/2025.
INDUSTRYADDRESSCONTACT
PharmaceuticalsAlembic Road, Vadodra Gujarat 390003Contact not found
Management
NamePosition Held
Mr. Chirayu AminChairman & CEO
Mr. Pranav AminManaging Director
Mr. Shaunak AminManaging Director
Mr. R K BahetiDirector - Finance & CFO
Mr. Jai DiwanjiIndependent Director
Mr. Ashok BaratIndependent Director
Ms. Geeta GoradiaIndependent Director
Mr. Manish KejriwalIndependent Director

FAQ

What is the intrinsic value of Alembic Pharmaceuticals Ltd and is it undervalued?

As of 13 April 2026, Alembic Pharmaceuticals Ltd's intrinsic value is ₹436.50, which is 35.52% lower than the current market price of ₹677.00, suggesting the stock is overvalued. This is calculated using the PE ratio method factoring in ROE (11.4 %), book value (₹271), dividend yield (1.62 %), and 5-year EPS CAGR.

What is the current share price and 52-week range of Alembic Pharmaceuticals Ltd?

Alembic Pharmaceuticals Ltd is trading at ₹677.00 as of 13 April 2026, with a FY2026-2027 high of ₹1,108 and low of ₹635. The stock is currently near its 52-week low. Market cap stands at ₹13,308 Cr..

How does Alembic Pharmaceuticals Ltd's P/E ratio compare to its industry?

Alembic Pharmaceuticals Ltd has a P/E ratio of 20.1, which is below the industry average of 53.84. Trading at a steep discount to peers could signal a value opportunity or reflect concerns about the company's fundamentals.

Is Alembic Pharmaceuticals Ltd financially healthy?

Key indicators for Alembic Pharmaceuticals Ltd: ROCE of 13.0 % is moderate. Dividend yield is 1.62 %.

Is Alembic Pharmaceuticals Ltd profitable and how is the profit trend?

Alembic Pharmaceuticals Ltd reported a net profit of ₹582 Cr in Mar 2025 on revenue of ₹6,672 Cr. Compared to ₹521 Cr in Mar 2022, the net profit shows an improving trend.

Does Alembic Pharmaceuticals Ltd pay dividends?

Alembic Pharmaceuticals Ltd has a dividend yield of 1.62 % at the current price of ₹677.00. The company pays dividends, though the yield is modest.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Alembic Pharmaceuticals Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE
Explore Industry-wise Stock Analysis Reports